Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
Biswajit Das(Frederick National Laboratory for Cancer Research), Chris Karlovich(Clovis Oncology (United States)), Lyndsay N. Harris(National Institutes of Health), Keith T. Flaherty(Cancer Research Center), Peter J. O’Dwyer(University of Pennsylvania), Rini Pauly(Frederick National Laboratory for Cancer Research), Jennifer S. LoCoco(Illumina (United States)), Traci Pawlowski(Illumina (United States)), Lisa M. McShane(National Cancer Institute), James H. Doroshow(National Cancer Institute), Vishnuprabha Rahul Kannan(Frederick National Laboratory for Cancer Research), Alice P. Chen(National Institutes of Health), Yuri Kotliarov(National Institutes of Health), Stanley R. Hamilton(City of Hope), Eric Greenbank(Frederick National Laboratory for Cancer Research), Li Chen(Harvard University), Ting-Chia Chang(Frederick National Laboratory for Cancer Research), Amanda Peach(Frederick National Laboratory for Cancer Research), Brandie Fullmer(Frederick National Laboratory for Cancer Research)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k